NeoStem, Inc. Announces the Addition of Jonathan Sackner-Bernstein, MD, Past FDA Official, as Vice President, Clinical Development and Regulatory Affairs

NEW YORK, April 11, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE Amex:NBS) ("NeoStem" or "the Company"), a leader in the cell therapy industry, is pleased to announce that Jonathan Sackner-Bernstein, MD, FACC joined the firm as Vice President of Clinical Development and Regulatory Affairs.